Liposomes Patents (Class 424/450)
  • Patent number: 10994017
    Abstract: Described herein are methods and compositions for nerve delivery molecules that carry imaging cargo or therapeutic cargo to the neurons or nerves.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: May 4, 2021
    Assignee: Avelas Biosciences, Inc.
    Inventors: Jesus Gonzalez, Junjie Liu, Marcel Miampamba
  • Patent number: 10993914
    Abstract: Irinotecan phospholipid liposomes with improved storage stability are provided, with related methods of treatment and manufacture. The irinotecan liposomes can have reduced formation of lyso-phosphatidylcholine (lyso-PC) during storage, and prior to administration to a patient.
    Type: Grant
    Filed: September 11, 2019
    Date of Patent: May 4, 2021
    Inventors: Daryl C. Drummond, Dmitri B. Kirpotin, Mark Eamon Hayes, Charles Noble, Kevin Kesper, Antoine M. Awad, Douglas J. Moore, Andrew J. O'Brien
  • Patent number: 10980869
    Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: April 20, 2021
    Assignee: Baylor Research Institute
    Inventors: Gerard Zurawski, Jacques F. Banchereau, Anne-Laure Flamar, Peter Klucar, Keiko Akagawa, Sandra Zurawski, SangKon Oh
  • Patent number: 10980840
    Abstract: The present disclosure provides novel methods for increasing ?-cell viability in islets by delivering RLIP76 polypeptides or GSTA4 polypeptides, or a combination thereof; or RLIP76 polynucleotides or GSTA4 polynucleotides, or a combination thereof, to the islets. The disclosure also provides novel methods for treating a disease or condition in a subject, such as type 1 diabetes mellitus, by delivering RLIP76 polypeptides or GSTA4 polypeptides, or a combination thereof; or RLIP76 polynucleotides or GSTA4 polynucleotides, or a combination thereof, to islets and transplanting the islets into the subject to treat the disease or condition. Kits and compositions including RLIP76 polypeptides or GSTA4 polypeptides, or a combination thereof; or RLIP76 polynucleotides or GSTA4 polynucleotides, or a combination thereof, are also provided to increase ?-cell viability.
    Type: Grant
    Filed: May 23, 2018
    Date of Patent: April 20, 2021
    Assignee: CITY OF HOPE
    Inventors: Sanjay Awasthi, Sushma Yadav, Ismail Al Abdullah, Fouad Kandeel, Brian McFadden, Indu Nair, Sharad S. Singhal
  • Patent number: 10982210
    Abstract: The invention provides compositions for delivery of cargo to cells. The invention also provides compositions that bind multiple agents simultaneously. The compositions are useful as therapeutics. Methods of using the compositions are also provided.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: April 20, 2021
    Assignee: Sixfold Bioscience Ltd.
    Inventors: George Foot, Anna Perdrix Rosell, Zuzanna Brzosko
  • Patent number: 10980798
    Abstract: Provide is a method of using a topoisomerase I inhibitor in treatment of cancer to reduce bone marrow suppression. The method includes administering to a subject in need thereof an effective amount of a pharmaceutical composition. The composition has at least one hydrophobic topoisomerase I inhibitor or a pharmaceutically acceptable salt thereof, and at least one polyethylene glycol (PEG) conjugated phospholipid, wherein the molar ratio of said PEG conjugated phospholipid to said hydrophobic topoisomerase I inhibitor or said pharmaceutically acceptable salt of said hydrophobic topoisomerase I inhibitor is about 0.45:1 to about 1.05:1.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: April 20, 2021
    Assignees: TAIWAN LIPOSOME COMPANY, LTD., TLC BIOPHARMACEUTICALS, INC.
    Inventors: Pei Kan, ChiaHung Hung, Keelung Hong, Yun-Long Tseng, Yung-Hsu Chan
  • Patent number: 10975112
    Abstract: Cell binding agent-drug conjugates comprising hydrophilic linkers, and methods of using such linkers and conjugates are provided.
    Type: Grant
    Filed: June 16, 2015
    Date of Patent: April 13, 2021
    Assignee: HANGZHOU DAC BIOTECH CO., LTD.
    Inventor: Robert Yongxin Zhao
  • Patent number: 10973761
    Abstract: The present invention relates to a formulation comprising a primary surfactant, a tocol phosphate, water, an active agent, and optionally an oil, wherein the active agent and/or the optional oil comprises a hydrophobic phase.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: April 13, 2021
    Assignee: Phosphagenics Limited
    Inventor: Mahmoud El-Tamimy
  • Patent number: 10973753
    Abstract: The invention relates to a dispersion of polymer particles stabilized with a stabilizer in a nonaqueous medium containing at least one hydrocarbon-based oil, the polymer of the particles being a C1-C4 alkyl (meth)acrylate polymer; the stabilizer being a C1-C4 alkyl (meth)acrylate polymer and optionally of a silicone macromonomer (I): the stabilizer being a polymer comprising from 50% to 100% by weight, relative to the total weight of the stabilizer, of C8-C22 alkyl acrylate, from 0 to 50% by weight of C1-C4 alkyl (meth)acrylate and optionally silicone macromonomer (I). The invention also relates to the composition comprising said dispersion of polymer particles. Cosmetic use for caring for and making up keratin materials.
    Type: Grant
    Filed: December 10, 2015
    Date of Patent: April 13, 2021
    Assignee: L'OREAL
    Inventors: Julien Portal, Xavier Schultze, Simon Taupin
  • Patent number: 10973935
    Abstract: A stabilized nanobubble can include a membrane that defines at least one internal void, which includes at least one gas. The membrane can include at least one lipid and at least one nonionic triblock copolymer that is effective to control the size of the nanobubble without compromising in vitro and in vivo echogenicity of the nanobubble.
    Type: Grant
    Filed: July 23, 2019
    Date of Patent: April 13, 2021
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Agata Exner, Tianyi Krupka, Luis Solorio
  • Patent number: 10973764
    Abstract: Methods for the treatment of stroke, such as stroke of undetermined origin, by administration of xenon (Xe)-loaded liposome compositions are provided. In some aspects, Xe is encapsulated in echogenic liposomes and release of Xe can be enhanced by application of ultrasound stimulation. Compositions for use in treating stroke, such as liposomes loaded with Xe or Xe in combination with H2 or H2S, are also provided.
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: April 13, 2021
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Shao-Ling Huang, Melvin E. Klegerman, Yong-Jian Geng, Hyunggun Kim, David D. Mcpherson
  • Patent number: 10968433
    Abstract: A method of generating one of podocyte progenitor cells and neural stem/progenitor cells comprising the steps of collecting a urine specimen from a patient; centrifuging the urine specimen; and removing the one of podocyte progenitor cells and neural stem/progenitor cells.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: April 6, 2021
    Assignee: BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY
    Inventor: Yuping Wang
  • Patent number: 10961289
    Abstract: The present invention relates to small molecules interfering with the conformational space of the TONSL ARD occupied by the histone H4 tail. These small molecules targets the binding pocket of TONSL encompassing the H4 residues K12-R23 and act by preventing or disrupting the binding of the H4 tail K12-R23 with the TONSL ARD via direct competition or via allosteric disruption of the binding pocket.
    Type: Grant
    Filed: November 29, 2019
    Date of Patent: March 30, 2021
    Assignees: The University of Copenhagen, Memorial Sloan-Kettering Cancer Center
    Inventors: Anja Groth, Giulia Saredi, Hongda Huang, Colin Hammond, Dinshaw Patel
  • Patent number: 10961188
    Abstract: Disclosed herein is a compound of Formula I, wherein R1 is a branched chain alkyl consisting of 10 to 31 carbons; R2 is a linear alkyl, alkenyl, or alkynyl consisting of 2 to 20 carbons, or a branched chain alkyl consisting of 10 to 31 carbons; L1 and L2 are the same or different, each a linear alkane of 1 to 20 carbons or a linear alkene of 2 to 20 carbons; X1 is S or O; R3 is a linear or branched alkylene consisting of 1 to 6 carbons; and R4 and R5 are the same or different, each a hydrogen or a linear or branched alkyl consisting of 1 to 6 carbons; or a pharmaceutically acceptable salt or solvate thereof.
    Type: Grant
    Filed: December 10, 2019
    Date of Patent: March 30, 2021
    Assignee: Arcturus Therapeutics, Inc.
    Inventors: Joseph E. Payne, Padmanabh Chivukula, Priya Karmali, Steven P. Tanis
  • Patent number: 10959951
    Abstract: The present invention provides methods of treating arthritis. A sustained release composition comprising liposomes and one or more therapeutic agent or a pharmaceutically acceptable salt thereof is administered to a subject in need thereof. The liposomes may be in an aqueous suspension. The sustained release composition can be administered intraarticularly.
    Type: Grant
    Filed: May 15, 2020
    Date of Patent: March 30, 2021
    Assignees: TAIWAN LIPOSOME CO., LTD., TLC BIOPHARMACEUTICALS, INC.
    Inventors: Keelung Hong, Luke S. S. Guo, Yun-Long Tseng, Sheue-Fang Shih, Po-Chun Chang, Chih-Chiang Tsai, Hong-Hui Lin
  • Patent number: 10952984
    Abstract: The present disclosure provides an all-trans retinoic acid injectable formulation and its application for a preparation of a pharmaceutical product for treating tumor. The all-trans retinoic acid injectable formulation includes all-trans retinoic acid and solubilizers. The apparent solubility of the all-trans retinoic acid is increased from 0.01 mg/mL to 0.1 mg/mL or more. The injectable formulation can reduce the activity of an infiltrated immuno-suppressive cell population within blood or tumor tissue of a cancer patient, and improve immune clearing effects against tumors. It can be applied independently or together with other pharmaceutical products to inhibit tumor growth and prevent tumor recurrence.
    Type: Grant
    Filed: August 17, 2017
    Date of Patent: March 23, 2021
    Assignee: HIGHFIELD BIOPHARMACEUTICAL CORPORATION
    Inventors: Yuhong Xu, Xiaolong Chen, Anjie Zheng, Lieyi Wu
  • Patent number: 10954282
    Abstract: This invention provides nucleic acid molecules encoding the N-terminal 158 amino acids of secreted human Fibroblast Growth Factor Binding Protein 3 (NBP158), pharmaceutical compositions comprising NBP158 polypeptide, and methods for treating metabolic disorders and conditions using such nucleic acids, polypeptides, or pharmaceutical compositions.
    Type: Grant
    Filed: December 9, 2014
    Date of Patent: March 23, 2021
    Inventor: Wentao Zhang
  • Patent number: 10945953
    Abstract: Provided is a composition including a dispersion medium including: an aqueous solution; a first active ingredient; a flavor agent; and a first type of polymer; and a dispersed phase including: a population of particles, each particle including: a core including: a second active ingredient a second type of polymer; and an aqueous solution; a shell, substantially surrounding the core, the shell including: a third type of polymer; a plurality of lipophilic carriers; and a third active ingredient; and a plurality of emulsifying agents.
    Type: Grant
    Filed: September 14, 2020
    Date of Patent: March 16, 2021
    Assignee: Nulixir Inc.
    Inventor: Ehsan Moaseri
  • Patent number: 10940207
    Abstract: The present invention provides, among other things, compositions and methods of formulating nucleic acid-containing nanoparticles comprising no more than three distinct lipids components, one distinct lipid component being a sterol-based cationic lipid. In some embodiments, the present invention provides compositions and methods in which the lipid nanoparticles further comprise helper lipids and PEG-modified lipids. The resulting formulation comprises a high encapsulation percentage for nucleic acids.
    Type: Grant
    Filed: January 27, 2020
    Date of Patent: March 9, 2021
    Assignee: Translate Bio, Inc.
    Inventors: Frank DeRosa, Michael Heartlein, Shrirang Karve
  • Patent number: 10940209
    Abstract: Several embodiments of the present disclosure relate to glycotargeting therapeutics that are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent. In several embodiments, the compositions are configured to target the liver and deliver antigens to which tolerance is desired. Methods and uses of the compositions for induction of immune tolerance are also disclosed herein.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: March 9, 2021
    Assignee: École Polytechnique Fédérale de Lausanne (EPFL)
    Inventors: Jeffrey A. Hubbell, David Scott Wilson
  • Patent number: 10940111
    Abstract: A method of reducing a friction coefficient of a surface is disclosed herein, comprising attaching a water-soluble polymer to the surface, and contacting the water-soluble polymer with liposomes, thereby coating the surface with an amphiphilic lipid. Further disclosed herein are solutions comprising a water-soluble polymer attachable to the surface, liposomes, and an aqueous carrier, for reducing a friction coefficient of a surface, and methods utilizing same. Articles of manufacture comprising a substrate coated by a water-soluble polymer which is coated by an amphiphilic lipid are also described, as are uses and methods for treating a synovial joint disorder associated with increased articular friction.
    Type: Grant
    Filed: June 15, 2015
    Date of Patent: March 9, 2021
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Jacob Klein, Ronit Goldberg, Jasmine Seror, Weifeng Lin, Reut Mashiach
  • Patent number: 10940193
    Abstract: Methods and compositions for the treatment of Brucella induced diseases and disorders are disclosed herein. In preferred embodiments, the invention relates to vaccines. In additional embodiments, the invention relates to formulations capable of releasing said vaccines at a controlled rate of release in vivo. In further embodiments, the invention relates to modified strains of the bacteria Brucella melitensis and Brucella abortus. In still further embodiments, the invention relates to compositions that do not induce clinical symptoms or splenomegaly in a subject receiving said compositions.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: March 9, 2021
    Assignee: THE TEXAS A&M UNIVERSITY SYSTEM
    Inventors: Thomas A. Ficht, Allison Ficht, Renee Tsolis, Leslie Garry Adams, Angela M. Arenas-Gamboa
  • Patent number: 10943350
    Abstract: A fully automated method for detecting and measuring a target of interest such as vasculature, capable of processing whole slide images and extracting large number of targets of interest per slide. The method includes the steps of: (a) obtaining a digital image of a tissue specimen; (b) using a first set of mathematical algorithms based on objectively-defined criteria to isolate the one or more targets of interest from the slide, thereby detecting the one or more targets of interest; and (c) using a second set of mathematical algorithms based on objectively-defined criteria to construct boundaries around the detected targets of interest and obtain quantitative attributes of these one or more targets throughout the slide, thereby measuring the one or more targets.
    Type: Grant
    Filed: February 25, 2016
    Date of Patent: March 9, 2021
    Assignee: LONDON HEALTH SCIENCE CENTER RESEARCH INC.
    Inventors: Aaron Devin Ward, Yi Wen Xu, John Geoffrey Pickering
  • Patent number: 10933027
    Abstract: The present invention relates to a construct including a porous core, a cargo, and a spacer disposed between the core and the cargo. In some examples, the construct further includes an outer layer composed of a lipid, a polymer, or a combination thereof. Methods of making and employing such constructs are also described herein.
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: March 2, 2021
    Assignee: National Technology & Engineering Solutions of Sandia, LLC
    Inventors: Darryl Y. Sasaki, Oscar Negrete, Edwin A. Saada, Patrick F. Fleig, Scott Reed, Eric L. Qiao
  • Patent number: 10933131
    Abstract: The present invention relates to compositions and methods for immunomodulation which are effective for increasing conception rate in cows.
    Type: Grant
    Filed: July 25, 2017
    Date of Patent: March 2, 2021
    Assignee: BAYER ANIMAL HEALTH GMBH
    Inventors: Jason Nickell, Daniel Keil, Albert Abraham, Warren Tully, Richard Gerhardus Martinu Olde Riekerink, Terry Settje, Leland Vickers, Stuart Nibbelink
  • Patent number: 10933032
    Abstract: Presented herein are methods for the treatment of oncological disorders by the co-administration of CoQ10 formulations and chemotherapeutic agents and/or surgery. The CoQ10 formulations may be at least one of intravenous, topical, or by inhalation. The chemotherapeutic agents may be at least one of antimetabolites or anthracyclines. Co-administration of the CoQ10 formulations may be prior to, concurrent or substantially concurrent with, intermittent with or subsequent to the administration of the chemotherapy.
    Type: Grant
    Filed: April 8, 2014
    Date of Patent: March 2, 2021
    Assignee: Berg LLC
    Inventors: Niven Rajin Narain, Rangaprasad Sarangarajan
  • Patent number: 10927383
    Abstract: In certain aspects, the disclosure relates to compositions comprising modified Cas9 polyribonucleotides and methods of use, as well as Cas9 polynucleotides and polyribonucleotides.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: February 23, 2021
    Assignee: ethris GmbH
    Inventors: Manish Kumar Aneja, Rebekka Kubisch-Dohmen, Christian Plank, Carsten Rudolph
  • Patent number: 10927418
    Abstract: Diagnostic methods for identifying cancer bearing subjects appropriate for treatment with CPX-351 include genetic and ex vivo testing of cells from a candidate subject. Combination treatment with CPX-351 and FLT-3 inhibitors improve CPX-351 uptake and toxicity.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: February 23, 2021
    Assignees: Celator Pharmaceuticals, Inc., Oreoon Health & Science University
    Inventors: Max Gordon, Paul Tardi, Jeffrey Tyner, Lawrence Mayer
  • Patent number: 10925831
    Abstract: This invention relates to use of a platinum-acridine liposomal formulation and uses thereof in treating cancer in a subject.
    Type: Grant
    Filed: August 28, 2018
    Date of Patent: February 23, 2021
    Assignee: Wake Forest University
    Inventors: Ulrich Bierbach, Song Ding, Christopher L. Hackett
  • Patent number: 10918701
    Abstract: The present disclosure provides a delivery system comprising (i) a physiologically acceptable carrier and (ii) a proteolytic enzyme or effector thereof for use in a method for relaxing fibers within a subject's oral cavity. In some embodiments, the relaxation is for use in tooth manipulation (particularly repositioning). In some embodiments, the method involves the use of the proteolytic enzyme or effector thereof at a concentration effective to cause relaxation of fibers between the tooth's alveolar bone and gingiva while maintaining integrity of the fibers surrounding the tooth. Also disclosed herein are methods for fiber relaxation and/or repositioning of tooth making use of the proteolytic enzyme or effector thereof.
    Type: Grant
    Filed: January 20, 2019
    Date of Patent: February 16, 2021
    Assignee: TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED
    Inventors: Avraham D. Schroeder, Assaf Yosef Zinger, Avishay Herman
  • Patent number: 10918598
    Abstract: Disclosed is a water-in-oil-in-water (W/O/W) double emulsion including a first water phase, an oil phase and a second water phase, wherein the W/O/W double emulsion is disposed in an isotonic solution, and related methods of making the W/O/W double emulsion. Also disclosed is a method of making an artificial antigen presenting cell including: providing a W/O/W double emulsion that is stored in an isotonic solution, wherein the W/O/W double emulsion includes a peptide associated with a Major Histocompatibility (pMHC) complex or a glycolipid antigen associated with a CD1d molecule, and a costimulatory molecule; and transferring the W/O/W double emulsion to an electrolyte solution, wherein the double emulsion undergoes a morphological transformation to become the artificial antigen presenting cell. Also disclosed is a method of drug delivery including administering to a subject a unilamellar vesicle containing the drug.
    Type: Grant
    Filed: December 9, 2015
    Date of Patent: February 16, 2021
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Abraham P. Lee, Derek Vellejo, Crystal Rapier
  • Patent number: 10912834
    Abstract: Compositions containing a complex that contains a cation with alkyl chains and a macromolecule anion, and methods of making and using are disclosed. The compositions are typically charge neutral and a liquid at room temperature and standard pressure. The macromolecule anions may be nucleic acids, peptides, proteins, and/or carbohydrates. The compositions have enhanced penetration across the skin barrier (stratum corneum) and into the skin cells, delivering the macromolecules to the skin cells. The compositions are topically applied to the skin and are particularly useful for treatment of skin conditions.
    Type: Grant
    Filed: August 29, 2017
    Date of Patent: February 9, 2021
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Michael Zakrewsky, Samir Mitragotri
  • Patent number: 10912838
    Abstract: The present invention provides a vesicle, a conjugate, a composition comprising the vesicle or the conjugate, for use in delivering a drug to the brain, and a method for administering the same. The composition of the present invention is a composition for administration to a subject according to a dosing regimen, comprising a carrier for drug delivery, wherein the dosing regimen comprises administering the composition to a subject who has been fasted or caused to have hypoglycemia and inducing an increase in blood glucose level in the subject, and the carrier is modified at the outer surface thereof with a GLUT1 ligand.
    Type: Grant
    Filed: February 22, 2018
    Date of Patent: February 9, 2021
    Assignees: THE UNIVERSITY OF TOKYO, NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY
    Inventors: Kazunori Kataoka, Yasutaka Anraku, Nobuhiro Nishiyama, Kanjiro Miyata, Takehiko Ishii, Yu Matsumoto, Yu Fukusato, Akihiro Mizoguchi, Takanori Yokota, Hiroya Kuwahara, Kazutaka Nishina, Hidehiro Mizusawa
  • Patent number: 10905661
    Abstract: This application relates to methods and compositions for the administration of disulfiram (DSF) and heavy metals zinc and copper for the treatment and prevention of medical conditions, such as cancer. DSF and copper as well as DSF and zinc form active complexes that have been shown to be effective in the treatment of cancers. However, as described herein, DSF is incompatible with either copper or zinc for simultaneous oral administration. Included herein are improved methods and oral dosage forms comprising DSF and copper and DSF and zinc in fixed dose combinations that are configured to temporally stagger release of either DSF and copper or DSF and zinc after ingestion.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: February 2, 2021
    Assignee: Cantex Pharmaceuticals, Inc.
    Inventor: Stephen Marcus
  • Patent number: 10905738
    Abstract: Synthetic peptides that are modulators of smooth muscle tone and compositions thereof, including pharmaceutical compositions containing a peptide, make it possible to treat indications in those in need of modulation of the smooth muscle tone, including, for example, benign prostate hyperplasia (BPH), Raynaud's syndrome, Pulmonary Arterial hypertension (PAH), systemic arterial hypertension (SAH) and hyper-reactivity of airways associated with asthma, COPD, pulmonary fibrosis, silicosis, allergic bronchopulmonary aspergillosis, hereditary angioedema, and neonatal hypoxemic respiratory failure. Although makeable in other ways, the synthetic peptides are makeable by recombinant methods or synthetic pathways.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: February 2, 2021
    Assignee: Biozeus Desenvolvimento De Produtos Biofarmacêuticos
    Inventors: Caio Victor Machado França do Nascimento, Diego Allonso Rodrigues dos Santos da Silva, Perla Villani Borges da Silva, Maria Elena De Lima Perez Garcia, Carolina Nunes da Silva, Adriano Monteiro de Castro Pimenta, Marcella Nunes de Melo Braga, Paulo Gustavo Sampaio Lacativa, Iron Francisco de Paula Junior, Gerhard Max Gross
  • Patent number: 10905657
    Abstract: The invention relates to a solid dispersion comprising Coenzyme Q10 and a phospholipid, in the presence of a cellulosic derivative and/or a polymeric material selected from the group consisting of polyvinylpyrrolidone, polyvinyl acetate, poly (methacrylic acid, methyl methacrylate), poloxamers, chitosan, alginates, hyaluronic acid, pectin, pullulan, cyclodextrins, starch polymers, D-alpha-tocopheryl polyethylene glycol 1000 succinate.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: February 2, 2021
    Assignee: Indena S.P.A.
    Inventors: Daniele Ciceri, Federico Peterlongo, Massimo Ronchi
  • Patent number: 10898582
    Abstract: Disclosed herein, is a bi-functional allosteric protein-drug molecule comprising a targeting moiety, one or more biological binding domains, and one or more therapeutic agents, wherein the therapeutic agent is allosterically bound to the biological binding domain. Also described herein, are methods of incorporating a bi-functional allosteric protein-drug molecule comprising a targeting moiety, one or more biological binding domains that captures the therapeutic agent without the formation of a chemical bond, and one or more therapeutic agents; physiologically acceptable compositions including them; and methods of administering the bi-functional allosteric protein-drug molecule to patients for the treatment of cancer.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: January 26, 2021
    Assignee: UNIVERSITY OF UTAH RESEARCH FOUNDATION
    Inventors: Youngwook Won, David A. Bull, Kwangsuk Lim
  • Patent number: 10894956
    Abstract: Described herein are phospholipid nanogels that can contain a low concentration (less than about 250 ?Units/?L) of an exoglycosidase enzyme. Also described herein are systems and devices that can contain a phospholipid nanogel that can contain a low concentration (less than about 250 ?Units/?L) of an exoglycosidase enzyme. Also described herein are methods of using the phospholipid nanogels described herein and devices and systems that can contain a phospholipid nanogel described herein.
    Type: Grant
    Filed: March 5, 2018
    Date of Patent: January 19, 2021
    Assignee: West Virginia University
    Inventors: Lisa Holland, Srikanth Gattu
  • Patent number: 10888572
    Abstract: A hydrated lecithin carrier vesicle composition includes lecithin and a triglyceride source or fatty acid in conditioned water. The disclosed compositions may be used for controlling appetite, weight loss, modulating effects from alcohol consumption, and/or delivering active agents to the small intestine.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: January 12, 2021
    Assignee: BIO-UP MIMETIC TECHNOLOGIES, INC.
    Inventors: Donald F. Hodgson, Crispin G. S. Eley
  • Patent number: 10888622
    Abstract: A nanocomplex containing a delivery agent and a pharmaceutical agent. The nanocomplex has a particle size of 50 to 1000 nm, the delivery agent binds to the pharmaceutical agent via non-covalent interaction or covalent bonding, and the pharmaceutical agent is a modified peptide or protein formed of a peptide or protein and an added chemical moiety that contains an anionic group, a disulfide group, a hydrophobic group, a pH responsive group, a light responsive group, a reactive oxygen species responsive group, or a combination thereof.
    Type: Grant
    Filed: May 13, 2014
    Date of Patent: January 12, 2021
    Assignee: Trustees of Tufts College
    Inventors: Qiaobing Xu, Ming Wang
  • Patent number: 10881735
    Abstract: Phase change nanodroplet conjugates and methods of making and using thereof are provided. The phase change nanodroplet conjugates include a nanodroplet having a gaseous precursor on the interior and an outer shell such as a lipid monolayer, a lipid bilayer, or a polymer layer. The phase change nanodroplet conjugates can have one or more nanoparticles attached to the outer layer, e.g. via a linker. The nanoparticles can include therapeutic, prophylactic, or diagnostic nanoparticles. The phase change nanodroplet conjugates can be used for the targeted delivery of a therapeutic, prophylactic, or diagnostic nanoparticle to a target region in a subject in need thereof. The methods can include applying an effective amount of ultrasound radiation to the target region to stimulate vaporization of the gaseous precursor followed by cavitation of the resultant bubble conjugate and release or dispersing of drug or drugs inside the liposomes. Methods of making phase change nanodroplet conjugates are also provided.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: January 5, 2021
    Assignee: Arizona Board of Regents on behalf of the University of Arizona
    Inventors: Theodore Trouard, Terry Matsunaga, Marek Romanowski
  • Patent number: 10883104
    Abstract: Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein (a) [apo(a)]. In certain embodiments, the apo(a) targeting oligomeric compounds are conjugated to N-Acetylgalactosamine. Also disclosed herein are conjugated oligomeric compounds targeting apo(a) for use in decreasing apo(a) to treat, prevent, or ameliorate diseases, disorders or conditions related to apo(a) and/or Lp(a). Certain diseases, disorders or conditions related to apo(a) and/or Lp(a) include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The conjugated oligomeric compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof.
    Type: Grant
    Filed: February 7, 2018
    Date of Patent: January 5, 2021
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze, Mark J. Graham
  • Patent number: 10874725
    Abstract: A treatment of Alzheimer's disease and other disorders involving protein misfolding or aggregation is provided by enhancing or sustaining an antibody response against predominantly directed against pathological protein aggregates or neo-epitopes present on pathogenic forms of said protein or protein complex. Furthermore, therapeutic methods are described, wherein ex vivo stimulated antigen-selected peripheral blood lymphocytes are regrafted into the cognate donor.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: December 29, 2020
    Assignee: New York University
    Inventors: Karsten Henco, Roger Nitsch, Jan Grimm, Anja Zeller, Marcel Maier
  • Patent number: 10874130
    Abstract: Steviol glycoside solutions, and methods of making steviol glycoside solutions, are described. The steviol glycoside solutions are clear and stable, and have clear solution stability, for extended periods of time.
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: December 29, 2020
    Assignee: PURE CIRCLE USA Inc.
    Inventors: Grace Kim, Marquita L. Johnson, Avetik Markosyan, John Martin, Kian Pin Tan
  • Patent number: 10874683
    Abstract: This disclosure relates to certain N4-hydroxycytidine derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of a Zika virus infection.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: December 29, 2020
    Assignee: Emory University
    Inventors: George R. Painter, David B. Guthrie, Gregory R. Bluemling, Michael R. Natchus
  • Patent number: 10874733
    Abstract: The present invention relates to an immunity enhancing composition including an immune response modulator having a novel structure and, more specifically, to an immunity enhancing composition and a use of the same, wherein the immunity enhancing composition includes a lipopolysaccharide (LPS) analogue with reduced toxicity, and a cationic liposome. The present invention overcomes the physicochemical instability of a liposome, is advantageous in terms of production, transportation, and storage, and improves stability, thus being beneficial as an immune delivery system. In addition, the present invention includes an immune response modulator, and a cationic liposome, and thus exhibits an enhanced immunity-improving effect compared to the case in which an immune response modulator is used alone.
    Type: Grant
    Filed: October 30, 2017
    Date of Patent: December 29, 2020
    Assignee: EYEGENE INC.
    Inventors: Yang Je Cho, Kwangsung Kim, Na Gyong Lee, Shin Ae Park
  • Patent number: 10875841
    Abstract: Small molecule stimulators of steroid receptor coactivator-3 (SRC-3) and methods of their use as cardioprotective agents are provided. The small molecule stimulators are useful for promoting cardiac protection and repair and vascular regeneration after myocardial infarction. The compounds are also useful in preventing cardiac hypertrophy and collagen deposition and improving cardiac post-infarction function.
    Type: Grant
    Filed: August 29, 2019
    Date of Patent: December 29, 2020
    Assignee: BAYLOR COLLEGE OF MEDICINE
    Inventors: Bert W. O'Malley, David Michael Lonard, Yongcheng Song
  • Patent number: 10872313
    Abstract: A method for adjudicating reimbursement for venom derived allergens between a pharmacist and a reimbursing entity comprises obtaining National Drug Codes (NDC's) for a plurality of venom derived allergens, storing in a central control database the obtained NDC's in association with an associated AWP and associated information for the venom derived allergen, which associated information includes translation information to allow practitioners to determine from a desired diluted level and number of doses of a desired NDC carrying venom derived antigen and a known dilution procedure how to translate back to the amount of base concentration of the NDC carrying venom derived antigen used to create the desired diluted level and number of doses, and determining if any of the NDC's in the central control database are contained within the third-party database and, if not, transferring the associated NDC's not in the third-party database to the third-party database.
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: December 22, 2020
    Assignee: ROCA MEDICAL LTD.
    Inventors: James Strader, Jovan Hutton Pulitzer
  • Patent number: 10864280
    Abstract: Disclosed herein are nanodroplet compositions composed of a copolymer with a hydrophilic block and a hydrophobic block, a poloxamer, an oil, an anti¬cancer agent, and optionally a lyoprotectant. The nanodroplet compositions exhibit low toxicity and are biodegradable, provide for slow, sustained release of the anti-cancer agent at tumor sites, and result in a greater reduction of tumor volume when administered to subjects with cancer as compared to several commercially-available products. Furthermore, the nanodroplet compositions can be imaged and their progress through the body tracked with magnetic resonance spectroscopy or ultrasound.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: December 15, 2020
    Inventor: Der-Yang Tien
  • Patent number: 10864168
    Abstract: Provided are lipid membrane microcapsules encapsulating or containing bioactives, and methods of production and use.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: December 15, 2020
    Assignee: The Regents of the University of California
    Inventors: Nitin Nitin, Stephen Young, Jean Vandergheynst